Target Audience
This activity is intended for hematologists, hematology-oncology fellows, medical oncologists and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma (DLBCL).

Learning Objectives
Upon completion of this activity, participants should be able to

• Identify patients with newly diagnosed DLBCL for whom CD79b-targeted therapy as a component of first-line treatment would be appropriate.
• Apply available clinical research findings in the formation of evidence-based approaches for the treatment of relapsed/refractory (R/R) DLBCL in patients who are unfit for intensive therapy.
• Evaluate the mechanisms of action, available clinical trial findings and spectrum and frequency of toxicities associated with various CD19-directed therapies approved for R/R DLBCL.
• Appraise the biological rationale for, recently presented research findings with and the potential role of CD30-targeted antibody-drug conjugate-based therapy for R/R DLBCL.
• Consider published research data with and the current clinical role of bispecific antibodies targeting CD20 x CD3 in R/R DLBCL.
• Counsel appropriate patients regarding the potential benefits of participation in clinical studies evaluating novel agents and strategies for DLBCL.

CE Credit
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation, Support and Credit Statements
In support of improving patient care, Medical Learning Institute, Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support Statement
This CE activity is supported through educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc and AbbVie Inc, and Incyte Corporation.

Physician Continuing Medical Education
Medical Learning Institute, Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure and Conflict of Interest Policy
Medical Learning Institute, Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy.

FACULTY  — The following faculty reported relevant financial relationships with ineligible entities:

Dr Nowakowski — Consulting Agreements: AbbVie Inc, ADC Therapeutics, Bantam Pharmaceutical, Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Curis Inc, Daiichi Sankyo Inc, Debiopharm, F Hoffmann-La Roche Ltd, Fate Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Kymera Therapeutics, MEI Pharma Inc, MorphoSys, Ryvu Therapeutics, Seagen Inc, Selvita, TG Therapeutics Inc, Zai Lab.

Dr Sehn — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Seagen Inc, Teva Oncology; Contracted Research: Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: CARGO Therapeutics.

MODERATOR  — Dr Flowers — Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation.

Planning Committee and Content/Peer Reviewers — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This symposium is planned and provided by Medical Learning Institute, Inc and Research To Practice. This accredited CE activity is an independent satellite symposium in conjunction with the Society of Hematologic Oncology 2024 Annual Meeting and is supported by ADC Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc and AbbVie Inc, and Incyte Corporation.

George R Brown Convention Center
1001 Avenida de las Americas
Houston, TX 77010
Main Phone: (713) 853-8000

Meeting Room
Level 3 in Grand Ballroom C (Theater 2)

Directions
The George R Brown Convention Center is the main venue for the SOHO 2024 Annual Meeting.